Personalised mRNA melanoma vaccine cuts risk of recurrence or death in phase III trial

Summary

A personalised mRNA-based melanoma vaccine, intismeran, significantly reduces the risk of cancer recurrence or death within two years, according to new clinical trial results. The vaccine is custom-made to target genetic mutations unique to each individual's melanoma. It is reported to be the first individualised cancer vaccine to show positive results in a phase III clinical trial, and one report describes the results as a 'foundational shift' in cancer treatment that lets scientists harness the immune system in a more personalised way. Australian coverage presents it as a world-first breakthrough with Australia at its heart, and the scientists involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.

Timeline

1. The Guardian

   23 Oct 2026, 04:27 UTCSource ↗

   The Guardian reports that a personalised mRNA melanoma vaccine, intismeran, significantly reduces the risk of cancer recurrence or death within two years, and is the first individualised cancer vaccine to show positive results in a phase III trial.

2. ABC

   23 Oct 2026, 07:08 UTCSource ↗

   ABC reports that a world-first cancer vaccine has been shown to radically reduce the risk of melanoma recurrence and death, presenting it as a transformational breakthrough with Australia at its heart.

3. BBC

   23 Oct 2026, 07:49 UTCSource ↗

   BBC reports that the first personalised cancer vaccine cuts the risk of disease returning in a major trial, and that the scientists involved say the results could mark a turning point in cancer treatment.